Baicalein inhibits the pharmacokinetics of simvastatin in rats via regulating the activity of CYP3A4

References

• Chen Z, Xiang Y, Bao B, Wu X, Xia Z, You J, Nie H. 2018. Simvastatin improves cerebrovascular injury caused by ischemia‑reperfusion through NF-κB-mediated apoptosis via MyD88/TRIF signaling. Molecular Med Rep. 18:3177–3184.
   PubMed Web of Science ®Google Scholar
• Chen Q, Yin C, Li Y, Yang Z, Tian Z. 2021. Pharmacokinetic interaction between peimine and paeoniflorin in rats and its potential mechanism. Pharm Biol. 59(1):129–133.
   PubMed Web of Science ®Google Scholar
• Cho YA, Choi JS, Burm JP. 2011. Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: a possible role of P-glycoprotein and CYP3A4 inhibition by baicalein. Pharmacol Rep. 63(4):1066–1073.
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S, Sleight P, Peto R. 2004. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 363:757–767.
   PubMed Web of Science ®Google Scholar
• Ding B, Ji X, Sun X, Zhang T, Mu S. 2020. In vitro effect of pachymic acid on the activity of cytochrome P450 enzymes. Xenobiotica. 50(8):913–918.
   PubMed Web of Science ®Google Scholar
• Izzo C, Carrizzo A, Alfano A, Virtuoso N, Capunzo M, Calabrese M, De Simone E, Sciarretta S, Frati G, Oliveti M, et al. 2018. The impact of aging on cardio and cerebrovascular diseases. IJMS. 19(2):481–511.
   Google Scholar
• Jiang F, Choi JY, Lee JH, Ryu S, Park ZW, Lee JG, Na HS, Lee SY, Oh WY, Chung MW, et al. 2017. The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition. Pharmacogenomics. 18(5):459–469.
   PubMed Web of Science ®Google Scholar
• Ju A, Li YY, Qu Z, Li Q. 2017. Impact of the herbal breviscapine on the pharmacokinetics of simvastatin in rats: the involvement of CYP3A4. Drug Res. 67(05):271–274.
   Google Scholar
• Kitzmiller JP, Luzum JA, Baldassarre D, Krauss RM, Medina MW. 2014. CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort. Pharmacogenet Genomics. 24(10):486–491.
   PubMed Web of Science ®Google Scholar
• Lendahl U, Nilsson P, Betsholtz C. 2019. Emerging links between cerebrovascular and neurodegenerative diseases-a special role for pericytes. EMBO Rep. 20(11):e48070.
   PubMed Web of Science ®Google Scholar
• Li C, Kim M, Choi H, Choi J. 2011. Effects of baicalein on the pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by baicalein. Arch Pharm Res. 34(11):1965–1972.
   PubMed Web of Science ®Google Scholar
• Li C, Lin G, Zuo Z. 2011. Pharmacological effects and pharmacokinetics properties of Radix Scutellariae and its bioactive flavones. Biopharm Drug Dispos. 32(8):427–445.
   PubMed Web of Science ®Google Scholar
• Li Y, Qin J, Wu H, Xu Y, Zhang L, Su K, Cui Y, Wang H. 2020. In vitro inhibitory effect of lysionotin on the activity of cytochrome P450 enzymes. Pharm Biol. 58(1):695–700.
   PubMed Web of Science ®Google Scholar
• Liang W, Huang X, Chen W. 2017. The effects of baicalin and baicalein on cerebral ischemia: a review. Aging Dis. 8(6):850–867.
   PubMed Web of Science ®Google Scholar
• Lin CC, Shieh DE. 1996. The anti-inflammatory activity of Scutellaria rivularis extracts and its active components, baicalin, baicalein and wogonin. Am J Chin Med. 24(1):31–36.
   PubMed Web of Science ®Google Scholar
• Manikandan P, Nagini S. 2018. Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets. 19:38–54.
   PubMed Web of Science ®Google Scholar
• Mendes P, Robles PG, Mathur S. 2014. Statin-induced rhabdomyolysis: a comprehensive review of case reports. Physiother Can. 66(2):124–132.
   PubMed Web of Science ®Google Scholar
• Noh K, Nepal MR, Jeong KS, Kim SA, Um YJ, Seo CS, Kang MJ, Park PH, Kang W, Jeong HG, et al. 2015. Effects of baicalin on oral pharmacokinetics of caffeine in rats. Biomol Ther. 23(2):201–206.
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Tobert JA. 2004. Simvastatin: a review. Expert Opin Pharmacother. 5(12):2583–2596.
   PubMed Web of Science ®Google Scholar
• Shi R, Zhu D, Wei Z, Fu N, Wang C, Liu L, Zhang H, Liang Y, Xing J, Wang X, et al. 2018. Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting endothelial-to-mesenchymal transition. Life Sci. 207:442–450.
   PubMed Web of Science ®Google Scholar
• Tian J, Sun S, Zhao Z, Li X. 2019. Pharmacokinetic interaction between Shuanghuanglian and azithromycin injection: a nonlinear mixed-effects model analysis in rats. Xenobiotica. 49(11):1344–1351.
   PubMed Web of Science ®Google Scholar
• Wang GQ, Xie YM, Wang LX, Wang Q, Jia PP, Feng B. 2017. Analysis of drug combination characteristics of Qingkailing injection for treating abnormal inflammatory factors in real world. Zhongguo Zhong Yao Za Zhi. 42(10):1984–1990.
   PubMedGoogle Scholar
• Yang S, Wang H, Yang Y, Wang R, Wang Y, Wu C, Du G. 2019. Baicalein administered in the subacute phase ameliorates ischemia-reperfusion-induced brain injury by reducing neuroinflammation and neuronal damage. Biomed Pharmacother. 117:109102–109113.
   PubMed Web of Science ®Google Scholar
• Zhang J, Shang H, Zheng W, Hu J, Xu H, Wang H, Zhang L, Ren M, Zhang B. 2010. Systematic review on the compatibility of Shuanghuanglian injection combined with western medical injections. J Evid Based Med. 3(1):27–36.
   PubMedGoogle Scholar
• Zhen YQ, Kong DZ, Ren LM. 2014. An overview of effects of traditional medicine on pharmacokinetics of western medicine. Yao Xue Xue Bao. 49(2):175–182.
   PubMedGoogle Scholar
• Zhou SF. 2008. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 9(4):310–322.
   PubMed Web of Science ®Google Scholar